Blueprint Medicines Co. (NASDAQ:BPMC) Receives Average Rating of "Hold" from Brokerages

Shares of Blueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) have been given an average recommendation of "Hold" by the twenty-one analysts that are currently covering the company, Marketbeat Ratings reports. Fifteen equities research analysts have rated the stock with a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $129.71.

A number of equities analysts have recently commented on the company. Wall Street Zen upgraded Blueprint Medicines from a "sell" rating to a "hold" rating in a report on Friday, May 2nd. JPMorgan Chase & Co. reaffirmed a "neutral" rating and set a $129.00 price target (down from $130.00) on shares of Blueprint Medicines in a research report on Monday. Needham & Company LLC downgraded shares of Blueprint Medicines from a "moderate buy" rating to a "hold" rating and set a $130.00 price objective for the company. in a research note on Monday. Guggenheim downgraded shares of Blueprint Medicines from a "strong-buy" rating to a "hold" rating in a research note on Tuesday. Finally, Stephens lowered shares of Blueprint Medicines from a "strong-buy" rating to a "hold" rating and reduced their target price for the company from $150.00 to $135.00 in a report on Tuesday.

Blueprint Medicines Trading Down 0.2%

BPMC stock traded down $0.20 on Wednesday, hitting $127.90. 4,441,993 shares of the company were exchanged, compared to its average volume of 1,096,996. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80. The stock has a market capitalization of $8.26 billion, a price-to-earnings ratio of -118.42 and a beta of 0.83. Blueprint Medicines has a twelve month low of $73.04 and a twelve month high of $128.36. The business's fifty day moving average is $93.96 and its two-hundred day moving average is $95.39.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.32). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. The company had revenue of $149.41 million for the quarter, compared to analysts' expectations of $158.31 million. During the same period in the prior year, the firm earned $1.40 earnings per share. The firm's quarterly revenue was up 55.5% on a year-over-year basis. As a group, research analysts forecast that Blueprint Medicines will post -1.28 earnings per share for the current year.

Insiders Place Their Bets

In other Blueprint Medicines news, Director Jeffrey W. Albers sold 5,000 shares of the business's stock in a transaction on Tuesday, May 27th. The shares were sold at an average price of $101.14, for a total transaction of $505,700.00. Following the completion of the sale, the director now owns 146,630 shares in the company, valued at $14,830,158.20. The trade was a 3.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Christina Rossi sold 2,274 shares of the stock in a transaction on Monday, May 5th. The stock was sold at an average price of $101.75, for a total transaction of $231,379.50. Following the sale, the chief operating officer now directly owns 66,992 shares in the company, valued at $6,816,436. This trade represents a 3.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 14,574 shares of company stock valued at $1,465,528 in the last ninety days. Corporate insiders own 4.21% of the company's stock.

Institutional Investors Weigh In On Blueprint Medicines

A number of institutional investors have recently modified their holdings of the business. Intrust Bank NA grew its holdings in Blueprint Medicines by 3.4% in the 1st quarter. Intrust Bank NA now owns 3,557 shares of the biotechnology company's stock worth $315,000 after buying an additional 118 shares in the last quarter. Fifth Third Bancorp boosted its position in Blueprint Medicines by 4.7% during the 1st quarter. Fifth Third Bancorp now owns 3,221 shares of the biotechnology company's stock worth $285,000 after acquiring an additional 146 shares during the period. Covestor Ltd grew its stake in shares of Blueprint Medicines by 15.9% in the first quarter. Covestor Ltd now owns 1,128 shares of the biotechnology company's stock worth $100,000 after purchasing an additional 155 shares in the last quarter. Torray Investment Partners LLC increased its holdings in shares of Blueprint Medicines by 1.1% during the first quarter. Torray Investment Partners LLC now owns 16,679 shares of the biotechnology company's stock valued at $1,476,000 after purchasing an additional 180 shares during the period. Finally, Headlands Technologies LLC raised its stake in shares of Blueprint Medicines by 25.0% during the first quarter. Headlands Technologies LLC now owns 936 shares of the biotechnology company's stock valued at $83,000 after purchasing an additional 187 shares in the last quarter.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.